Lincoln Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
LINCOLN
Pharmaceuticals
Screen Lincoln Pharmaceuticals share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹490.55
▼
-6.60 (-1.33%)
Share Price BSE
₹490.10
▼
-6.50 (-1.31%)
Market Cap
₹957.52 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
1.35
EPS (TTM)
₹41.11
Dividend Yield
0.37%
Debt to Equity
-
52W High
₹835.70
52W Low
₹472.65
Operating Margin
16.00%
Profit Margin
11.70%
Revenue (TTM)
₹171.00
EBITDA
₹33.00
Net Income
₹20.00
Total Assets
₹797.00
Total Equity
₹672.00
Lincoln Pharmaceuticals Share Price History - Stock Screener Chart
Screen LINCOLN historical share price movements with interactive charts. Analyze price trends and patterns.
Lincoln Pharmaceuticals Company Profile - Fundamental Screener
Screen Lincoln Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for LINCOLN shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE405C01035
Lincoln Pharmaceuticals Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen LINCOLN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 797 | 700 | 587 | 534 | 452 | 389 | 366 | 347 | 305 | 275 |
| Current Assets | 500 | 447 | 367 | 353 | 309 | 248 | 224 | 218 | 181 | 147 |
| Fixed Assets | 182 | 179 | 151 | 132 | 111 | 123 | 121 | 117 | 103 | 99 |
| Liabilities | ||||||||||
| Total Liabilities | 797 | 700 | 587 | 534 | 452 | 389 | 366 | 347 | 305 | 275 |
| Current Liabilities | 19 | 15 | 13 | 11 | 10 | 10 | 11 | 18 | 22 | 34 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 672 | 593 | 503 | 433 | 366 | 314 | 270 | 225 | 193 | 141 |
| Share Capital | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 16 |
| Reserves & Surplus | 652 | 573 | 482 | 413 | 346 | 293 | 249 | 204 | 172 | 117 |
Screen LINCOLN income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 171 | 169 | 161 | 156 | 171 | 158 | 150 | 158 | 165 | 143 | 116 | 140 | 146 | 130 | 105 |
| Expenses | 138 | 130 | 142 | 123 | 133 | 125 | 124 | 117 | 125 | 115 | 96 | 107 | 112 | 107 | 85 |
| EBITDA | 33 | 39 | 20 | 33 | 38 | 33 | 25 | 41 | 40 | 28 | 21 | 33 | 35 | 23 | 19 |
| Operating Profit % | 16.00% | 15.00% | 16.00% | 16.00% | 18.00% | 15.00% | 13.00% | 20.00% | 20.00% | 15.00% | 15.00% | 20.00% | 21.00% | 14.00% | 17.00% |
| Depreciation | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 |
| Interest | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Profit Before Tax | 29 | 35 | 16 | 29 | 35 | 30 | 22 | 38 | 37 | 26 | 17 | 31 | 32 | 21 | 17 |
| Tax | 9 | 8 | 5 | 8 | 8 | 6 | 4 | 10 | 9 | 6 | 4 | 9 | 8 | 6 | 6 |
| Net Profit | 20 | 28 | 12 | 21 | 26 | 24 | 19 | 28 | 28 | 19 | 13 | 22 | 24 | 15 | 11 |
| EPS | 9.98 | 13.82 | 5.78 | 10.37 | 13.15 | 11.82 | 9.28 | 14.00 | 13.81 | 9.49 | 6.27 | 10.79 | 11.84 | 7.49 | 5.50 |
Lincoln Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen LINCOLN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 93 | 63 | 39 | 76 | 69 | 75 | 53 | 27 | 25 | 45 |
| Investing Activities | -79 | -57 | -37 | -78 | -64 | -31 | -18 | -12 | -26 | -42 |
| Financing Activities | -6 | -5 | -5 | -3 | -6 | -38 | -36 | -11 | 0 | -3 |
| Net Cash Flow | 8 | 1 | -2 | -5 | -1 | 7 | -1 | 4 | 0 | 0 |
Screen LINCOLN shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 49.78% | 49.78% | 49.78% | 49.53% | 49.78% | 49.78% | 49.78% | 47.00% |
| FII Holding | 5.00% | 5.14% | 4.72% | 3.93% | 3.95% | 5.19% | 5.16% | 0.00% |
| DII Holding | 0.01% | 0.01% | 0.01% | 0.05% | 0.04% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 36.64% | 36.27% | 36.26% | 37.36% | 37.10% | 36.14% | 36.71% | 37.03% |
| Other Holding | 8.59% | 8.81% | 9.23% | 9.13% | 9.14% | 8.89% | 8.35% | 15.97% |
| Shareholder Count | 31,867 | 31,784 | 32,370 | 31,375 | 29,967 | 31,330 | 31,848 | 29,088 |
Lincoln Pharmaceuticals Dividend Screener - Share Yield Analysis
Screen LINCOLN dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.80 | 0.37% |
| 2024-March | ₹1.80 | 0.33% |
| 2023-March | ₹1.50 | 0.26% |
| 2022-March | ₹1.50 | 0.44% |
| 2021-March | ₹1.50 | 0.48% |
| 2020-March | ₹1.50 | 0.67% |
| 2019-March | ₹1.50 | 1.16% |
| 2018-March | ₹1.50 | 0.71% |
| 2017-March | ₹1.20 | 0.56% |
Lincoln Pharmaceuticals Index Membership - Market Screener Classification
Screen LINCOLN by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Lincoln Pharmaceuticals Market Events Screener - Corporate Actions
Screen LINCOLN market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 1.80 /share | -7.23% | ||
| Dividend | ₹ 1.50 /share | -4.87% | ||
| Dividend | ₹ 1.50 /share | 16.16% | ||
| Dividend | ₹ 1.80 /share | 28.22% | ||
| Annual General Meeting | NA | -4.13% | ||
| Dividend | ₹ 1.50 /share | 19.82% | ||
| Annual General Meeting | NA | -2.11% | ||
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 0.52% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -2.07% |
| 2025-05-22 | 2025-05-22 | Quarterly Result Announcement | NA | 2.21% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -4.25% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -5.02% |
Lincoln Pharmaceuticals Competitors Screener - Peer Comparison
Screen LINCOLN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Lincoln Pharmaceuticals Company Announcements - News Screener
Screen LINCOLN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-29 | Closure of Trading Window | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-13 | UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2025 | View |
| 2025-11-13 | Board Meeting Outcome for UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2025 | View |
| 2025-11-05 | Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30.09.2025. | View |
| 2025-10-28 | Minutes Of 31St Annual General Meeting Of The Company. | View |
| 2025-10-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-03 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-10-03 | Submission Of E-Voting Results Of 31St AGM Along With The Scrutinizer Report As Per Regulation 44 Of SEBI (LODR) Regulation 2015. | View |
| 2025-09-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-23 | Closure of Trading Window | View |
| 2025-09-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-09-06 | General Updates | View |
| 2025-09-06 | Reg. 34 (1) Annual Report. | View |
| 2025-09-06 | Notice Of 31St Annual General Meeting Of The Company. | View |
| 2025-08-29 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-08-29 | Intimation Of Book Closure And Record Date For The Purpose Of 31St Annual General Meeting And Final Dividend For The Financial Year 2024-25. | View |
| 2025-08-29 | Corporate Action-Fixes Book Closure For Determining The Dividend If Approved At The AGM | View |
| 2025-08-26 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |